Table 1: Various drugs/therapies and their effect on LP(a) reduction [11,36].


Main Effect

Reduction effect on LP(a) levels

1.      Inclisiran (PCK9i)

LDL-C reduction

Minus 20-26%

2.      Mipomersen

Inhibits Apo(b)-100 synthesis

Minus 26.4%

3.      Lomitapide

Inhibits VLDL synthesis

Minus 3%

4.      Anacetrapib

Promotes HDL and Inhibits LDL synthesis

Minus 25%

5.      Estrogens

Promotes HDL and Inhibits LDL synthesis

Minus 10-15%

6.      Niacin


Minus 20%

7.      Lipid apheresis therapy

LP(a) reduction

Minus 35%

8.      ARO-ANG (ANGPTL3i)

LDL-C and TG reduction


9.      Nicotinic acids

Inhibits LP(a) promoters via AMP

Minus 20-30%

10.   SLN 360

Targets LP(a)

Minus 46-90%


TG reduction


12.   Olpasiran

Targets LP(a)

Minus 80-97%

13.   AKCEA-APO(a)-LRx (Pelacarsen)

Targets LP(a)

Minus 80%

PCK9i: Proprotein Convertase Kexin type 9 Inhibitor; ANGPTL3: Angiopoietin-like Protein 3 Inhibitor; APOC-IIIi: Apolipoprotein C-III Inhibitor; VLDL: Very Low-Density Lipoprotein; HDL: High Density Lipoprotein; LDL: Low Density Lipoprotein; TG: Triglyceride